Furosemide

Introduction Overview

Generic Name

furosemide

Brand Name

Lasix

Dosage Form

oral tablets, oral solution, injectable solution

Drug Class

Loop diuretics

Pharmacokinetics

Absorption:
Furosemide is absorbed primarily from the gastrointestinal tract following oral administration. It exhibits variable bioavailability, with reported values ranging from 50% to 100%, largely dependent on the formulation and gastrointestinal conditions. Peak plasma concentrations typically occur within 1 to 2 hours after oral dosing, though onset of diuresis may be delayed in some patients. Food intake can reduce the rate but not the extent of absorption. In cases of congestive heart failure or edema, absorption may be somewhat reduced due to gut edema.

Distribution:
Furosemide is extensively bound to plasma proteins (>95%), mainly albumin. This high protein binding limits its volume of distribution, which is approximately 0.1 to 0.2 L/kg. Because of its protein binding, furosemide does not readily cross the blood-brain barrier but can be detected in breast milk, potentially affecting nursing infants. The drug is distributed to the site of action in the renal tubules via active tubular secretion rather than passive glomerular filtration.

Metabolism:
Furosemide undergoes limited hepatic metabolism. Approximately 10% to 20% of the dose is metabolized in the liver to inactive metabolites via conjugation pathways, including glucuronidation. The metabolism pathway is minor, so liver impairment generally affects elimination to a lesser extent compared to renal impairment.

Elimination:
The primary route of elimination is renal excretion. Around 60% to 90% of the administered furosemide dose is excreted unchanged in the urine through active secretion by the organic acid transporters in the proximal renal tubules. The plasma elimination half-life ranges from 1.5 to 2 hours in healthy individuals but can be prolonged in renal impairment. The drug is also excreted in bile to a small extent. Renal function critically influences elimination, making dose adjustments important in patients with renal failure. Hemodialysis only minimally removes furosemide due to its high protein binding.

Dosage Forms

Available Dosage Forms:
- Oral tablets: 20 mg, 40 mg, 80 mg
- Oral solution: 10 mg/mL
- Injectable solution: 10 mg/mL for intravenous or intramuscular use

Dosages for Adults and Adolescents:
The initial dose for conditions such as edema due to congestive heart failure, liver cirrhosis, nephrotic syndrome, or renal failure is typically 20 to 80 mg orally once. Doses may be repeated after 6 to 8 hours, incrementally increasing by 20 or 40 mg until the desired diuretic effect is achieved. Maintenance dosing generally involves administration once or twice daily, often at 8 am and 2 pm to reduce nocturia.

For pulmonary edema, the usual initial oral dose is 80 mg per day divided into two 40 mg doses.

Maximum doses in severe edematous states may be as high as 600 mg/day, though such high dosing requires close monitoring for toxicity.

Pediatric dosages are weight-based, starting at 2 mg/kg orally once. If diuresis is inadequate, the dose may be increased by 1 to 2 mg/kg at intervals no shorter than 6 to 8 hours, with a maximum dose around 6 mg/kg.

Specific Patient Populations:
- In patients with renal impairment, higher doses may be required due to reduced renal secretion.
- Dosage adjustments are critical in hepatic cirrhosis with ascites to avoid excessive fluid and electrolyte disturbances.
- In elderly patients, start with lower doses and titrate carefully due to increased sensitivity and risk of dehydration or electrolyte imbalances.
- Patients on concurrent ototoxic drugs require cautious dosing to minimize risk of hearing loss.
- The dosing regimen should be individualized based on clinical response and laboratory monitoring, including electrolytes and renal function.

Mechanism Of Action

Furosemide exerts its pharmacological effects primarily by inhibiting the sodium-potassium-chloride co-transporter (NKCC2) located in the thick ascending limb of the loop of Henle in the nephron. This transporter is essential for sodium and chloride reabsorption, as well as for the generation of the medullary concentration gradient necessary for water reabsorption downstream.

By blocking the NKCC2 transporter, furosemide causes a significant increase in the excretion of sodium, chloride, and consequently water, leading to diuresis and reduction of extracellular fluid volume. This effect results in decreased preload and reduced edema in conditions such as congestive heart failure, liver cirrhosis, and renal disease.

Furosemide’s inhibition of the thick ascending loop also reduces the lumen-positive transepithelial potential difference, which normally drives the paracellular reabsorption of divalent cations like calcium and magnesium. Therefore, furosemide increases the urinary excretion of calcium and magnesium, which has clinical implications, especially in patients susceptible to electrolyte disturbances.

At the cellular level, furosemide's blockade interferes with electrolyte homeostasis, which can influence vascular tone indirectly via changes in blood volume and neurohormonal activation. Clinically, this results in decreased blood pressure, making furosemide useful in the management of hypertension, particularly in volume-dependent hypertension.

Compared to other diuretics such as thiazides, furosemide acts more proximally on the nephron and produces a more potent and rapid diuretic effect. This makes it the diuretic of choice in conditions requiring prompt and effective volume removal.

Extensive clinical studies have demonstrated that furosemide effectively reduces morbidity associated with fluid overload and can be safely used across diverse patient populations, with careful monitoring.

Pharmacological Actions

Potent diuresis by inhibiting sodium and chloride reabsorption in the thick ascending limb of the loop of Henle.
Reduction of extracellular fluid volume leading to decreased venous return and cardiac preload.
Increased renal excretion of water, sodium, chloride, potassium, calcium, and magnesium.
Lowering of blood pressure through volume depletion and secondary vasodilation.
Rapid onset of action suitable for emergency treatment of fluid overload and pulmonary edema.
Reduction of edema in conditions such as congestive heart failure, nephrotic syndrome, liver cirrhosis, and renal diseases.
Promotion of kaliuresis that may lead to hypokalemia if not monitored.
Induction of increased renin release due to volume depletion, potentially activating the renin-angiotensin system.
Influence on electrolyte balance, which can affect cardiac and neuromuscular function.
Decreased calcium reabsorption, which may be beneficial or detrimental depending on clinical context.
Potential ototoxicity at high doses or rapid intravenous administration due to effects on electrolyte transport in the ear.
Minimal metabolism and elimination primarily via renal excretion of unchanged drug.
Potentiation of the effect of other antihypertensive agents when used in combination therapy.
Ability to mobilize edematous fluid effectively even in patients with impaired renal function.
Interference with renal tubular transporters leading to altered handling of other drugs and endogenous substances.

Therapeutic Or Clinical Uses

Treatment of edema associated with congestive heart failure.
Management of edema caused by liver cirrhosis and ascites.
Reduction of edema related to nephrotic syndrome and other renal disorders.
Treatment of hypertension, either as monotherapy or in combination with other antihypertensives.
Management of acute pulmonary edema for rapid fluid removal.
Treatment of renal failure-related fluid overload.
Facilitation of diuresis in patients with electrolyte imbalances requiring fluid removal.
Use in hypercalcemia due to increased renal calcium excretion.
Supportive therapy in conditions causing fluid retention from various etiologies.
Emergency management of fluid overload states in hospitalized patients.
Adjunctive therapy in hypertension resistant to other drug classes.
Control of blood pressure in congestive heart failure to reduce cardiovascular risk.
Off-label use in conditions requiring potent diuresis and electrolyte modulation.
Short-term diuretic therapy during surgical procedures requiring volume control.
Fluid management in critically ill patients with severe edema.

Side Or Adverse Effects

Electrolyte imbalances such as hypokalemia, hyponatremia, hypomagnesemia, and hypocalcemia.
Dehydration and volume depletion leading to hypotension and dizziness.
Ototoxicity manifesting as tinnitus, hearing loss, or vertigo, especially with high doses or rapid IV administration.
Hyperglycemia and potential worsening of glucose control in diabetic patients.
Increased uric acid levels potentially precipitating gout flare-ups.
Renal impairment or acute kidney injury due to excessive diuresis and hypovolemia.
Photosensitivity reactions making skin more prone to sunburn.
Gastrointestinal disturbances including nausea, vomiting, diarrhea, or constipation.
Rashes or allergic reactions including sulfonamide-related hypersensitivity.
Muscle cramps, weakness, or spasms related to electrolyte abnormalities.
Blood dyscrasias such as thrombocytopenia or leukopenia in rare cases.
Headache, blurred vision, or dizziness due to blood pressure changes or electrolyte shifts.
Pancreatitis and liver function abnormalities reported in isolated cases.
Metabolic alkalosis secondary to increased bicarbonate reabsorption.
Fatigue and generalized malaise after prolonged therapy.

Precautions

Monitor renal function regularly to avoid potential kidney damage.
Periodic electrolyte monitoring is essential to prevent dangerous imbalances.
Use with caution in patients with sulfonamide allergy due to potential cross-reactivity.
Avoid abrupt changes in posture to minimize orthostatic hypotension and dizziness.
Adjust doses carefully in elderly patients due to increased sensitivity and risk of dehydration.
Use cautiously in patients with gout or hyperuricemia to prevent exacerbation.
Avoid concurrent use with nephrotoxic or ototoxic agents unless necessary with close monitoring.
Consider dose adjustments in patients with hepatic cirrhosis to prevent encephalopathy.
Avoid excessive sun exposure and use sunscreen due to increased photosensitivity risk.
Monitor blood glucose levels in diabetic patients as furosemide may increase blood sugar.
Patients with electrolyte disorders require careful management to avoid complications.
Ensure adequate hydration status without causing fluid overload or dehydration.
Inform patients about potential for increased urination and to avoid dehydration.
Avoid high doses over prolonged periods unless under strict medical supervision.
Be vigilant for signs of allergy or severe skin reactions.

Warnings

Contraindicated in patients who are unable to urinate (anuria).
High doses may cause irreversible ototoxicity and hearing loss.
Use caution in patients with electrolyte imbalances; can exacerbate hypokalemia or hyponatremia.
Avoid use during pregnancy unless clearly needed due to uncertain fetal risk.
Not recommended during breastfeeding as it may reduce milk production and pass into breast milk.
May cause severe dehydration and hypotension if fluid loss is excessive.
Risk of acute renal failure if volume depletion is not properly managed.
Use caution in patients with hepatic encephalopathy; diuresis can worsen condition.
Potential interaction with contrast dyes used in imaging may increase nephrotoxicity risk.
Abrupt discontinuation may lead to rebound fluid retention.
Patients with systemic lupus erythematosus should be monitored closely due to potential exacerbation.
May mask signs of infection due to volume changes.
Careful monitoring required when used with other antihypertensives to prevent hypotension.
Excessive dosing can lead to metabolic alkalosis and electrolyte disturbances.
Risk of thrombocytopenia and other hematologic abnormalities in rare cases.

Contraindication

Anuria or inability to produce urine.
Known hypersensitivity to furosemide or other sulfonamide-derived drugs.
Severe electrolyte depletion prior to correction.
Patients with hepatic coma or severe liver dysfunction where diuresis is contraindicated.
Hypovolemia or dehydration without adequate volume replacement.
Use with caution or avoidance in patients with known allergy to loop diuretics.
Congenital or acquired conditions that cause impairment of renal function without potential for recovery.
Pregnancy when risk outweighs benefit and safer alternatives exist.
Severe hypotension or shock states.
Patients receiving potassium-sparing diuretics who have hyperkalemia.
Use in neonates or premature infants without specialized monitoring.
History of severe idiosyncratic reaction to furosemide.
Concurrent use with other ototoxic drugs without specialist oversight.
In patients with marked hypokalemia uncorrected by supplementation.
Conditions where fluid removal is contraindicated due to circulatory shock.

Drug Interactions

Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and naproxen may decrease the diuretic and antihypertensive effects of furosemide.
Concurrent use with aminoglycoside antibiotics or cisplatin can enhance ototoxicity and nephrotoxicity.
Lithium levels may increase due to decreased renal clearance, risking toxicity.
Thiazide or potassium-sparing diuretics used concomitantly can alter electrolyte balance and increase risk of dysrhythmias.
Antihypertensive agents may have additive hypotensive effects when combined with furosemide.
Methotrexate clearance may be reduced leading to increased toxicity.
Chloral hydrate and phenytoin may interact, altering sedative or anti-epileptic drug levels.
Sucralfate can reduce furosemide absorption; doses should be separated by at least 2 hours.
Use with corticosteroids or amphotericin B can exacerbate hypokalemia.
Concurrent use with cyclosporine may increase risk of nephrotoxicity.
Drugs that prolong QT interval require caution due to electrolyte disturbances caused by furosemide.
Non-depolarizing muscle relaxants’ effects may be potentiated due to electrolyte imbalances.
Agents that increase blood sugar may have amplified effects.
Concurrent use of contrast dyes may further impair renal function.
Furosemide may reduce the efficacy of uricosuric agents used in gout.

Preparations Of The Drug

Lasix 20 mg oral tablets for daily dosing adjustments.
Lasix 40 mg oral tablets for intermediate dosing requirements.
Lasix 80 mg oral tablets for higher dose needs, often divided.
Lasix oral solution 10 mg/mL for patients unable to swallow tablets or requiring precise dosing.
Lasix injectable solution 10 mg/mL for intravenous or intramuscular administration, mainly in hospital settings.
Furoscix, an alternative brand offering subcutaneous administration options.
Prepackaged oral dosing kits ensuring accurate volume measurement for liquid forms.
Parenteral formulations intended for rapid onset in acute fluid overload conditions.
Generic furosemide formulations widely available as cost-effective alternatives.
Compounded formulations may be used in special populations under medical direction.
Special storage guidance to preserve efficacy—store at room temperature, protected from moisture and heat.
Labels and packaging include detailed dosage instructions and warnings.
Patient information leaflets emphasizing hydration guidelines and side effect profiles.
Combination therapy preparations are generally not available; must be administered alongside other agents separately.
Pediatric formulations exist in liquid form to facilitate dosing in children.